Theriva Biologics (TOVX)

• Market cap: $6.98M
• 1 day: 5.3%
• 5 days: -6.3%
• 1 month: -12.89%
• 3 months: -50.41%
• 6 months: -55.73%
• Year to date: -87.47%
• 1 year: -82.32%
• 5 years: -99.76%
• 10 years: -100%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Employees: 22